September 8, 2008 -- Chinese pharmaceutical companies, motivated by the premium placed on globally patented technologies by potential investors, are scrambling to apply for intellectual property protection in global markets, according to industry insiders. “Compared to the situation a decade ago, it should be obvious that Chinese pharmaceutical companies are much more aware of the importance of patents to protect their technologies, domestically and even globally, and also of the importance of not infringing on others’ [patents],” said Woody Wu, an investment manager with Mingly China Growth Fund. More details...
